Article
MECOM is a master repressor of myeloid differentiation through dose control of <i>CEBPA</i> in acute myeloid leukemia
2025-01-02
Abstract excerpt
Enhancer translocations, due to 3q26 rearrangements, drive out-of-context MECOM expression in an aggressive subtype of acute myeloid leukemia (AML). Direct depletion of MECOM using an endogenous auxin-inducible degron immediately upregulates expression of myeloid differentiation factor CEBPA . MECOM depletion is also accompanied by a severe loss of stem cells and gain of differentiation. MECOM exerts its inhibit...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- e88c719f-d817-5a3a-a421-9b9c0184d2a5
- DOI
- 10.1101/2025.01.02.631046
